Badr Moutaz Y, Basim Pratap, Hosny Khaled M, Rizg Waleed Y, Naveen N Raghavendra, Kurakula Mallesh, Alsulaimani Fayez, Safhi Awaji Y, Sabei Fahad Y, Alissa Mohammed, Alamoudi Abdulmohsin J
Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 24381, Saudi Arabia.
ThermoFisher Scientific, Cincinnati, OH 45237, USA.
Pharmaceuticals (Basel). 2023 Jun 25;16(7):925. doi: 10.3390/ph16070925.
Mucoadhesive nanosized crystalline aggregates (NCs) can be delivered by the gastrointestinal, nasal, or pulmonary route to improve retention at particular sites. Itopride hydrochloride (ITH) was selected as a drug candidate due to its absorption from the upper gastrointestinal tract. For drug localization and target-specific actions, mucoadhesive polymers are essential. The current work aimed to use second-generation mucoadhesive polymers (i.e., thiolated polymers) to enhance mucoadhesive characteristics. An ITH-NC formulation was enhanced using response surface methodology. Concentrations of Tween 80 and Polyvinyl pyrrolidone (PVP K-30) were selected as independent variables that could optimize the formulation to obtain the desired entrapment efficacy and particle size/diameter. It was found that a formulation prepared using Tween 80 at a concentration of 2.55% and PVP K-30 at 2% could accomplish the goals for which an optimized formulation was needed. Either xanthan gum (XG) or thiolated xanthan gum (TXG) was added to the optimized formulation to determine how they affected the mucoadhesive properties of the formulation. Studies demonstrated that there was an initial burst release of ITH from the ITH/NC/XG and ITH/NC/TXG in the early hours and then a steady release for 24 h. As anticipated, the TXG formulation had a better mucin interaction, and this was needed to ensure that the drug was distributed to tissues that produce mucus. Finally, at the measured concentrations, the ITH/NC showed minimal cytotoxicity against lung cells, indicating that it may have potential for additional in vivo research. The enhanced bioavailability and mean residence time of the designed mucoadhesive NC formulations were confirmed by pharmacokinetic studies.
粘膜粘附性纳米级结晶聚集体(NCs)可通过胃肠道、鼻腔或肺部途径给药,以提高在特定部位的滞留时间。由于盐酸伊托必利(ITH)可从上消化道吸收,因此被选为候选药物。对于药物定位和靶向特异性作用而言,粘膜粘附性聚合物至关重要。当前的工作旨在使用第二代粘膜粘附性聚合物(即硫醇化聚合物)来增强粘膜粘附特性。采用响应面法对ITH-NC制剂进行了优化。选择吐温80和聚乙烯吡咯烷酮(PVP K-30)的浓度作为自变量,以优化制剂,从而获得所需的包封率和粒径/直径。结果发现,使用浓度为2.55%的吐温80和2%的PVP K-30制备的制剂能够实现制备优化制剂的目标。将黄原胶(XG)或硫醇化黄原胶(TXG)添加到优化后的制剂中,以确定它们对制剂粘膜粘附性能的影响。研究表明,ITH从ITH/NC/XG和ITH/NC/TXG中在最初几个小时有一个初始突释,然后持续释放24小时。正如预期的那样,TXG制剂具有更好的粘蛋白相互作用,这对于确保药物分布到产生粘液的组织中是必要的。最后,在所测浓度下,ITH/NC对肺细胞显示出最小的细胞毒性,表明其可能有进行更多体内研究的潜力。药代动力学研究证实了所设计的粘膜粘附性NC制剂提高了生物利用度和平均驻留时间。